Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 21.88M shares rose 48.3% year over year, ahead of the +34.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 28.0% from the prior quarter. Over 3 fiscal years it compounded at +11.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +48.3% holds above the trailing-twelve-month pace of +34.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
21.88M+28.0% QoQ
Last fiscal yearDec 2025
17.09M+30.7% YoY
LTMMar 2026
18.01M+34.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.3%——
1 year+30.7%——
3-year CAGR+11.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
17.09M USD
Year-over-year change
+30.7%
4-year CAGR
+8.9%

Weighted Avg Shares vs competitors

How LYEL compares with its peers on the latest reported figures

  • LYEL's LTM Mar 2026 weighted avg shares of 18.01M shares is the lowest of the 11 companies compared; the peer median is 69.17M shares.
  • Its year-over-year change of +34.2% is the 2nd highest of 10, against a peer median of +9.3%.
  • Over three fiscal years its annual growth of +11.4% compares with a peer median of +15.2%.
LYEL Competitors Peer median
Weighted Avg Shares for LYEL and competitors
Company Period LTM YoY 3-year CAGR
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
ACIUAC Immune S.A.LTM Mar 202699.9M -2.5%+6.4%
CABACabaletta Bio, Inc.LTM Mar 202694.61M +91.6%+51.6%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
LRMRLarimar Therapeutics, Inc.LTM Mar 202678.18M +22.5%+41.5%
ALDXAldeyra Therapeutics, Inc.LTM Mar 202660.16M +1.0%+0.9%
KYTXKyverna Therapeutics, Inc.LTM Mar 202648.56M +12.5%+19.7%
GNLXGenelux CorporationLTM Mar 202636.38M +11.4%+14.8%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
AMRNAmarin Corporation plcLTM Mar 202620.78M +1.0%+1.1%
LYELLyell Immunopharma, Inc.LTM Mar 202618.01M +34.2%+11.4%
Peer median (excluding LYEL) 69.17M+9.3%+15.2%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.